Expertise in
22
conditions

Dr. Grzegorz Nowakowski

Hematology | Oncology
MN - Cancer
200 1st St SW, 
Rochester, MN 
Accepting New Patients
Expertise in
22
conditions
MN - Cancer
200 1st St SW, 
Rochester, MN 

Overview

Grzegorz Nowakowski is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota.

Dr. Nowakowski is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 239 peer reviewed articles and participating in 17 clinical trials. Dr. Nowakowski is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MN

Hospital Affiliations

Mayo Clinic Hospital Rochester

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MN - Cancer
200 1st St SW, Rochester, MN 55905
Other Locations
Mayo Clinic College Of Medicine And Science Oncology
200 1st St Sw, Rochester, MN 55905

Additional Areas of Focus

Dr. Nowakowski has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Radiation, Other
Study Phase: Not Applicable
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2025
Intervention Type: Other, Device
A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Enrollment Status: Terminated
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: JBH492 Anti-CCR7 Antibody-Drug Conjugate
Study Phase: Phase 1
A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
Enrollment Status: Completed
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Tafasitamab, Bendamustine
Study Phase: Phase 2/Phase 3
Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET
Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET
Enrollment Status: Terminated
Publish Date: May 26, 2025
Intervention Type: Drug, Biological, Other, Procedure
Study Drugs: Belinostat, Carfilzomib, Copanlisib Hydrochloride, Daratumumab, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Nivolumab, Obinutuzumab, Pembrolizumab, Rituximab, Romidepsin, Trastuzumab
Study Phase: Phase 1
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drug: Venetoclax
Study Phase: Phase 2
Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma
Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Drug, Biological, Other, Genetic
Study Drugs: Pegfilgrastim, Rituximab, Cyclophosphamide, Doxorubicin, Lenalidomide, Prednisone, Vincristine
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

238 Total Publications

Improved overall survival in classical Hodgkin lymphoma across therapeutic eras: A National Cancer Database study.
Improved overall survival in classical Hodgkin lymphoma across therapeutic eras: A National Cancer Database study.
Journal: British journal of haematology
Published: June 10, 2026
Similar Doctors
Expertise in
25
conditions
Dr. Stephen M. Ansell
Hematology | Oncology
Expertise in
25
conditions
Dr. Stephen M. Ansell
Hematology | Oncology
Referral may be required

MN - Cancer

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-923-2592
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Ansell is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Ansell is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Ansell is currently accepting new patients.

Expertise in
43
conditions
Dr. Ronald S. Go
Hematology | Oncology
Expertise in
43
conditions
Dr. Ronald S. Go
Hematology | Oncology
Referral may be required

MN - Cancer

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-512-1667
Languages Spoken:
English, Filipino, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Go is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Go is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Rosai-Dorfman Disease, Histiocytosis, Reticulohistiocytoma, Bone Marrow Transplant, and Splenectomy. Dr. Go is currently accepting new patients.

Expertise in
11
conditions
Dr. Francis K. Buadi
Hematology | Oncology
Expertise in
11
conditions
Dr. Francis K. Buadi
Hematology | Oncology
Referral may be required

MN - Cancer Transplant

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-910-0296
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Francis Buadi is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Buadi is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Smoldering Multiple Myeloma, POEMS Syndrome, and Bone Marrow Transplant. Dr. Buadi is currently accepting new patients.

Frequently Asked Questions about Dr. Grzegorz Nowakowski

How do I make an appointment with Dr. Grzegorz Nowakowski?

You can book an appointment with Dr. Grzegorz Nowakowski by calling their office at 507-923-2592. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Grzegorz Nowakowski a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Grzegorz Nowakowski is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Grzegorz Nowakowski specialize in?

While Dr. Grzegorz Nowakowski is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and B-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Grzegorz Nowakowski participate in research or clinical trials?

Yes. Dr. Grzegorz Nowakowski has published 238 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Grzegorz Nowakowski's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Grzegorz Nowakowski accept my insurance?

Dr. Grzegorz Nowakowski accepts most major insurance plans, including Blue Cross Blue Shield and Blue Shield of California. We recommend calling the office directly at 507-923-2592 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nowakowski's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile